• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Center for Biosimilars® Launches Education E-book for Biosimilar Stakeholders


The latest e-book from The Center for Biosimilars® offers insightful content on patient education, biosimilar development, and regulatory issues.

The Center for Biosimilars® has launched “Biosimilars 101: Practice Concerns, Market Acceptance, and the Biosimilars Pipeline,” an e-book resource for the health care community. This publication contains insightful analysis and guidance from key opinion leaders who are actively engaged in the day-to-day effort to understand biosimilar trends and bring these lower-cost agents to patients who need them.

“Biosimilars 101: Practice Concerns, Market Acceptance, and the Biosimilars Pipeline,” answers some of the most basic and common questions about these important agents: How should the patient-physician conversation about these agents be addressed? What biosimilars are available, and in what disease categories will they be available next? Have biosimilars been accepted, and what roadmap should a health care institution follow to achieve greater biosimilar savings and access for patients? And finally, where did biosimilars come from? What was the legislative intent and regulatory foundation that led to the development of an approval pathway for these copy biologics?

Biosimilars are approved by regulators as safe and efficacious versions of originator biologics with no clinically meaningful differences. Their acceptance and use in the United States and Europe has grown rapidly, and the number of companies worldwide that are joining the effort to produce these more-economical agents bodes well for efforts to bring down the soaring cost of biologics. Biosimilars accounted for $2.2 billion of savings on health care costs in the United States in 2019, according to the Association for Accessible Medicines. There is potential for even greater savings.

Indeed, as stated recently by Dan Kistner, group senior vice president for Pharmacy Solutions at Vizient, “One of the keys to managing costs for health systems is the adoption of biosimilars as they come on the market. There are now 12 biosimilars available and where there are 2 or more competitors, we have seen prices as much as 30% lower than the branded product. Providers and payers must now become better aligned to realize the full benefit that competition can offer in driving down the cost of care.”

“Biosimilars 101: Practice Concerns, Market Acceptance, and the Biosimilars Pipeline” is chock-full of helpful information for the health care provider, patient advocate, practice administrator, or industry professional who needs to keep up with developments in biosimilars or employ them for greater savings and access. Obtain your copy by clicking here.

Related Videos
Ha Kung Wong, JD.
Ha Kung Wong, JD
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Related Content
© 2024 MJH Life Sciences

All rights reserved.